Substituted sulfonamide derivatives, a process for their preparation, pharmaceutical compositions containing these compounds, and to the use of substituted sulfonamide derivatives in the treatment or inhibition of pain and/or various disorders or disease states.
[EN] QUINOXALINE COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS À BASE DE QUINOXALINE ET LEURS UTILISATIONS
申请人:MILLENNIUM PHARM INC
公开号:WO2015161142A1
公开(公告)日:2015-10-22
This invention provides compounds of formula I and subsets thereof: wherein T, J, R, R4, Rq, o, RA, and RB and subsets thereof are as described in the specification. The compounds are inhibitors of NAMPT and are thus useful for treating cancer, inflammatory conditions, or T-cell mediated autoimmune disease.
[EN] D3 RECEPTOR AGONIST COMPOUNDS; METHODS OF PREPARATION; INTERMEDIATES THEREOF; AND METHODS OF USE THEREOF<br/>[FR] COMPOSÉS AGONISTES DU RÉCEPTEUR D3; PROCÉDÉS DE PRÉPARATION; INTERMÉDIAIRES DE CEUX-CI; ET LEURS PROCÉDÉS D'UTILISATION
申请人:US HEALTH
公开号:WO2020210785A1
公开(公告)日:2020-10-15
Disclosed herein are novel compounds including dopamine D3 receptor agonists, compositions thereof, methods of use thereof, and processes of synthesizing the same. Further disclosed are D3R selective agonist compounds, specifically bitopic ligands comprising chirality.
Earlier we have reported the effect of arecoline thiazolidinone and morpholino arecolinederivatives as muscarinicreceptor 1 agonists in Alzheimer’s presenile dementia models. To elucidate further our Structure–Activity Relationship (SAR) studies on the chemistry and muscarinicreceptor 1 binding efficacy, a series of novel carboxamide derivatives of 2-(1-methyl-1,2,5,6-tetrahydropyridin-3-yl)morpholine
Compounds are provided which bind to and are agonists, antagonists or inverse agonists of the CB2 receptor, the compounds having the general formula
wherein, R
1
, R
2
, A, Y, X, Ar
1
and Ar
2
have the meanings given in the specification, and the preparation and use thereof. The compounds are valuable CB2 receptor modulators.